19 Jul Affinia Therapeutics
Rick Modi, CEO
Oct. 8 | 10:00am | FLW Ballroom G
Waltham, MA
(Private)
Affinia Therapeutics is pioneering a new class of rationally designed gene therapies to treat rare and prevalent diseases. The Affinia Rationally designed Therapeutics (ART) platform synergistically improves the efficacy, safety, and manufacturability of adeno-associated virus (AAV)-based gene therapies through the development of next-generation capsids, promoters, and manufacturing approaches. Affinia’s novel capsids have shown significantly improved tropism to cardiac muscle, skeletal muscle, or the CNS with more uniform tissue distribution than AAV9 in nonhuman primates. Affinia has multiple best-in-class or first-in-class preclinical programs in genetic cardiomyopathies and diseases of the CNS.
